{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T11:04:18Z","timestamp":1782299058402,"version":"3.54.5"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2023,10,13]],"date-time":"2023-10-13T00:00:00Z","timestamp":1697155200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,10,13]],"date-time":"2023-10-13T00:00:00Z","timestamp":1697155200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1007\/s10067-023-06787-2","type":"journal-article","created":{"date-parts":[[2023,10,13]],"date-time":"2023-10-13T08:02:44Z","timestamp":1697184164000},"page":"3225-3235","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Are all JAK inhibitors for the treatment of rheumatoid arthritis equivalent? An adjusted indirect comparison of the efficacy of tofacitinib, baricitinib, upadacitinib, and filgotinib"],"prefix":"10.1007","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-3827-8291","authenticated-orcid":false,"given":"Luc\u00eda","family":"Vallez-Valero","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-3725-0771","authenticated-orcid":false,"given":"Ingrid","family":"Gas\u00f3-Gago","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2595-5906","authenticated-orcid":false,"given":"\u00c1ngel","family":"Marcos-Fendian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8249-2771","authenticated-orcid":false,"given":"Gemma","family":"Garrido-Alejos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adri\u00e0","family":"Riera-Magall\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adri\u00e1n","family":"Plaza Diaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5079-613X","authenticated-orcid":false,"given":"Cristina","family":"Martinez-Molina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1438-8515","authenticated-orcid":false,"given":"Maria Ant\u00f2nia","family":"Mangues-Bafalluy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7738-6787","authenticated-orcid":false,"given":"H\u00e8ctor","family":"Corominas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,10,13]]},"reference":[{"key":"6787_CR1","volume-title":"Kelley\u2019s and Firesten\u2019s textbook of rheumatology","author":"G Firestein","year":"2017","unstructured":"Firestein G, Budd R, Gabriel S et al (2017) Kelley\u2019s and Firesten\u2019s textbook of rheumatology, 10th edn. Elsevier Saunders, Philadelphia","edition":"10"},{"issue":"2","key":"6787_CR2","first-page":"37","volume":"5","author":"P Chaudhari","year":"2008","unstructured":"Chaudhari P (2008) The impact of rheumatoid arthritis and biologics on employers and payers. Biotechnol Healthc 5(2):37\u201344","journal-title":"Biotechnol Healthc"},{"key":"6787_CR3","unstructured":"England BR, Mikuls TR (2021) Epidemiology of, risk factors for, and possible causes of rheumatoid arthritis. Uptodate. https:\/\/www.uptodate.com\/contents\/epidemiology-of-risk-factors-for-and-possible-causes-of-rheumatoid-arthritis. Accessed 16 Mar 2023"},{"key":"6787_CR4","volume-title":"Gu\u00eda de Pr\u00e1ctica Cl\u00ednica para el Manejo de Pacientes con Artritis Reumatoide","author":"Grupo de trabajo de la GUIPCAR","year":"2019","unstructured":"Grupo de trabajo de la GUIPCAR (2019) Gu\u00eda de Pr\u00e1ctica Cl\u00ednica para el Manejo de Pacientes con Artritis Reumatoide. Sociedad Espa\u00f1ola de Reumatolog\u00eda, Madrid"},{"key":"6787_CR5","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1001\/jama.2018.13103","volume":"320","author":"D Aletaha","year":"2018","unstructured":"Aletaha D, Smolen JS (2018) Diagnosis and management of rheumatoid arthritis. JAMA 320:1360. https:\/\/doi.org\/10.1001\/jama.2018.13103","journal-title":"JAMA"},{"key":"6787_CR6","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1136\/annrheumdis-2020-219012","volume":"80","author":"PG Traves","year":"2021","unstructured":"Traves PG, Murray B, Campigotto F et al (2021) JAK selectivity and the implications for clinical inhibition of pharmacodynamic cytokine signalling by filgotinib, upadacitinib, tofacitinib and baricitinib. Ann Rheum Dis 80:865\u2013875. https:\/\/doi.org\/10.1136\/annrheumdis-2020-219012","journal-title":"Ann Rheum Dis"},{"key":"6787_CR7","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1111\/j.1600-065X.2008.00754.x","volume":"228","author":"K Ghoreschi","year":"2009","unstructured":"Ghoreschi K, Laurence A, O\u2019Shea JJ (2009) Janus kinases in immune cell signaling. Immunol Rev 228:273\u2013287. https:\/\/doi.org\/10.1111\/j.1600-065X.2008.00754.x","journal-title":"Immunol Rev"},{"issue":"2","key":"6787_CR8","doi-asserted-by":"publisher","first-page":"e001673","DOI":"10.1136\/rmdopen-2021-001673","volume":"7","author":"SB Cohen","year":"2021","unstructured":"Cohen SB, Pope J, Haraoui B, Mysler E, Diehl A, Lukic T, Liu S, Stockert L, Germino R, Menon S, Shi H, Keystone EC (2021) Efficacy and safety of tofacitinib modified-release 11 mg once daily plus methotrexate in adult patients with rheumatoid arthritis: 24-week open-label phase results from a phase 3b\/4 methotrexate withdrawal non-inferiority study (ORAL Shift). RMD Open 7(2):e001673. https:\/\/doi.org\/10.1136\/rmdopen-2021-001673","journal-title":"RMD Open"},{"issue":"6","key":"6787_CR9","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1056\/NEJMoa1109071","volume":"367","author":"R Fleischmann","year":"2012","unstructured":"Fleischmann R, Kremer J, Cush J, Schulze-Koops H, Connell CA, Bradley JD, Gruben D, Wallenstein GV, Zwillich SH, Kanik KS, ORAL Solo Investigators (2012) Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis. N Engl J Med 367(6):495\u2013507. https:\/\/doi.org\/10.1056\/NEJMoa1109071","journal-title":"N Engl J Med"},{"issue":"10093","key":"6787_CR10","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/S0140-6736(17)31618-5","volume":"390","author":"R Fleischmann","year":"2017","unstructured":"Fleischmann R, Mysler E, Hall S, Kivitz AJ, Moots RJ, Luo Z, DeMasi R, Soma K, Zhang R, Takiya L, Tatulych S, Mojcik C, Krishnaswami S, Menon S, Smolen JS, ORAL Strategy investigators (2017) Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b\/4, double-blind, head-to-head, randomised controlled trial. Lancet 390(10093):457\u2013468. https:\/\/doi.org\/10.1016\/S0140-6736(17)31618-5 Epub 2017 Jun 16","journal-title":"Lancet"},{"issue":"4","key":"6787_CR11","doi-asserted-by":"publisher","first-page":"253","DOI":"10.7326\/0003-4819-159-4-201308200-00006","volume":"159","author":"J Kremer","year":"2013","unstructured":"Kremer J, Li ZG, Hall S, Fleischmann R, Genovese M, Martin-Mola E, Isaacs JD, Gruben D, Wallenstein G, Krishnaswami S, Zwillich SH, Koncz T, Riese R, Bradley J (2013) Tofacitinib in combination with nonbiologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis: a randomized trial. Ann Intern Med 159(4):253\u2013261. https:\/\/doi.org\/10.7326\/0003-4819-159-4-201308200-00006","journal-title":"Ann Intern Med"},{"issue":"3","key":"6787_CR12","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1002\/art.37816","volume":"65","author":"D van der Heijde","year":"2013","unstructured":"van der Heijde D, Tanaka Y, Fleischmann R, Keystone E, Kremer J, Zerbini C, Cardiel MH, Cohen S, Nash P, Song YW, Tegzov\u00e1 D, Wyman BT, Gruben D, Benda B, Wallenstein G, Krishnaswami S, Zwillich SH, Bradley JD (2013) Connell CA; ORAL Scan Investigators. Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: twelve-month data from a twenty-four-month phase III randomized radiographic study. Arthritis 65(3):559\u2013570. https:\/\/doi.org\/10.1002\/art.37816","journal-title":"Arthritis"},{"issue":"6","key":"6787_CR13","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1056\/NEJMoa1112072","volume":"367","author":"RF van Vollenhoven","year":"2012","unstructured":"van Vollenhoven RF, Fleischmann R, Cohen S, Lee EB, Garc\u00eda Meijide JA, Wagner S, Forejtova S, Zwillich SH, Gruben D, Koncz T, Wallenstein GV, Krishnaswami S, Bradley JD, Wilkinson B, ORAL Standard Investigators (2012) Tofacitinib or adalimumab versus placebo in rheumatoid arthritis. N Engl J Med 367(6):508\u2013519. https:\/\/doi.org\/10.1056\/NEJMoa1112072 Erratum in: N Engl J Med. 2013 Jul 18;369(3):293","journal-title":"N Engl J Med"},{"key":"6787_CR14","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/S0140-6736(12)61424-X","volume":"381","author":"GR Burmester","year":"2013","unstructured":"Burmester GR, Blanco R, Charles-Schoeman C et al (2013) Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial. Lancet Lond Engl 381:451\u2013460. https:\/\/doi.org\/10.1016\/S0140-6736(12)61424-X","journal-title":"Lancet Lond Engl"},{"issue":"1","key":"6787_CR15","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1136\/annrheumdis-2016-210094","volume":"76","author":"M Dougados","year":"2017","unstructured":"Dougados M, van der Heijde D, Chen YC, Greenwald M, Drescher E, Liu J, Beattie S, Witt S, de la Torre I, Gaich C, Rooney T, Schlichting D, de Bono S, Emery P (2017) Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study. Ann Rheum Dis 76(1):88\u201395. https:\/\/doi.org\/10.1136\/annrheumdis-2016-210094 Epub 2016 Sep 29. Erratum in: Ann Rheum Dis. 2017 Sep;76(9):1634","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"6787_CR16","first-page":"732","volume":"38","author":"Z Li","year":"2020","unstructured":"Li Z, Hu J, Bao C, Li X, Li X, Xu J, Spindler AJ, Zhang X, Xu J, He D, Li Z, Wang G, Yang Y, Wu H, Ji F, Tao H, Zhan L, Bai F, Rooney TP, Zerbini CAF (2020) Baricitinib in patients with rheumatoid arthritis with inadequate response to methotrexate: results from a phase 3 study. Clin Exp Rheumatol 38(4):732\u2013741 Epub 2020 May 20","journal-title":"Clin Exp Rheumatol"},{"issue":"7","key":"6787_CR17","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1056\/NEJMoa1608345","volume":"376","author":"PC Taylor","year":"2017","unstructured":"Taylor PC, Keystone EC, van der Heijde D, Weinblatt ME, Del Carmen ML, Reyes Gonzaga J, Yakushin S, Ishii T, Emoto K, Beattie S, Arora V, Gaich C, Rooney T, Schlichting D, Macias WL, de Bono S, Tanaka Y (2017) Baricitinib versus placebo or adalimumab in rheumatoid arthritis. N Engl J Med 376(7):652\u2013662. https:\/\/doi.org\/10.1056\/NEJMoa1608345","journal-title":"N Engl J Med"},{"key":"6787_CR18","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1056\/NEJMoa1507247","volume":"374","author":"MC Genovese","year":"2016","unstructured":"Genovese MC, Kremer J, Zamani O et al (2016) Baricitinib in patients with refractory rheumatoid arthritis. N Engl J Med 374:1243\u20131252. https:\/\/doi.org\/10.1056\/NEJMoa1507247","journal-title":"N Engl J Med"},{"key":"6787_CR19","doi-asserted-by":"publisher","first-page":"2513","DOI":"10.1016\/S0140-6736(18)31116-4","volume":"391","author":"MC Genovese","year":"2018","unstructured":"Genovese MC, Fleischmann R, Combe B et al (2018) Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial. Lancet Lond Engl 391:2513\u20132524. https:\/\/doi.org\/10.1016\/S0140-6736(18)31116-4","journal-title":"Lancet Lond Engl"},{"issue":"10139","key":"6787_CR20","doi-asserted-by":"publisher","first-page":"2503","DOI":"10.1016\/S0140-6736(18)31115-2","volume":"391","author":"GR Burmester","year":"2018","unstructured":"Burmester GR, Kremer JM, Van den Bosch F, Kivitz A, Bessette L, Li Y, Zhou Y, Othman AA, Pangan AL, Camp HS (2018) Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEXT): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 391(10139):2503\u20132512. https:\/\/doi.org\/10.1016\/S0140-6736(18)31115-2 Epub 2018 Jun 18","journal-title":"Lancet"},{"issue":"11","key":"6787_CR21","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.1002\/art.41032","volume":"71","author":"R Fleischmann","year":"2019","unstructured":"Fleischmann R, Pangan AL, Song IH, Mysler E, Bessette L, Peterfy C, Durez P, Ostor AJ, Li Y, Zhou Y, Othman AA, Genovese MC (2019) Upadacitinib versus placebo or adalimumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase III, double-blind, randomized controlled trial. Arthritis Rheumatol 71(11):1788\u20131800. https:\/\/doi.org\/10.1002\/art.41032 Epub 2019 Aug 28","journal-title":"Arthritis Rheumatol"},{"issue":"7","key":"6787_CR22","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1136\/annrheumdis-2020-219214","volume":"80","author":"B Combe","year":"2021","unstructured":"Combe B, Kivitz A, Tanaka Y, van der Heijde D, Simon JA, Baraf HSB, Kumar U, Matzkies F, Bartok B, Ye L, Guo Y, Tasset C, Sundy JS, Jahreis A, Genovese MC, Mozaffarian N, Landew\u00e9 RBM, Bae SC, Keystone EC, Nash P (2021) Filgotinib versus placebo or adalimumab in patients with rheumatoid arthritis and inadequate response to methotrexate: a phase III randomised clinical trial. Ann Rheum Dis 80(7):848\u2013858. https:\/\/doi.org\/10.1136\/annrheumdis-2020-219214 Epub 2021 Jan 27","journal-title":"Ann Rheum Dis"},{"key":"6787_CR23","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1001\/jama.2019.9055","volume":"322","author":"MC Genovese","year":"2019","unstructured":"Genovese MC, Kalunian K, Gottenberg J-E et al (2019) Effect of filgotinib vs placebo on clinical response in patients with moderate to severe rheumatoid arthritis refractory to disease-modifying antirheumatic drug therapy: the FINCH 2 randomized clinical trial. JAMA 322:315\u2013325. https:\/\/doi.org\/10.1001\/jama.2019.9055","journal-title":"JAMA"},{"key":"6787_CR24","doi-asserted-by":"crossref","first-page":"5","DOI":"10.4321\/S1135-57272014000100002","volume":"88","author":"A Tobias","year":"2014","unstructured":"Tobias A, Catal\u00e1-L\u00f3pez F, Roqu\u00e9 i Figuls M (2014) Development of an Excel spreadsheet for meta-analysis of indirect and mixed treatment comparisons. Rev Esp Salud P\u00fablica 88:5\u201315","journal-title":"Rev Esp Salud P\u00fablica"},{"key":"6787_CR25","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1016\/s0895-4356(97)00049-8","volume":"50","author":"HC Bucher","year":"1997","unstructured":"Bucher HC, Guyatt GH, Griffith LE, Walter SD (1997) The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. J Clin Epidemiol 50:683\u2013691. https:\/\/doi.org\/10.1016\/s0895-4356(97)00049-8","journal-title":"J Clin Epidemiol"},{"key":"6787_CR26","unstructured":"European Medicines Agency. Committee for Medicinal Products for Human Use (2019). Rinvoq\u00ae (upadacitinib) public assessment report (EMEA\/H\/C\/004760\/0000). https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/rinvoq-epar-public-assessment-report_en.pdf. Accessed 16 Mar 2023"},{"issue":"9685","key":"6787_CR27","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/S0140-6736(09)60506-7","volume":"374","author":"JS Smolen","year":"2009","unstructured":"Smolen JS, Kay J, Doyle MK, Landew\u00e9 R, Matteson EL, Wollenhaupt J, Gaylis N, Murphy FT, Neal JS, Zhou Y, Visvanathan S, Hsia EC, Rahman MU, GO-AFTER study investigators (2009) Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial. Lancet 374(9685):210\u2013221. https:\/\/doi.org\/10.1016\/S0140-6736(09)60506-7 Epub 2009 Jun 26. Erratum in: Lancet. 2009 Oct 24;374(9699):1422","journal-title":"Lancet"},{"key":"6787_CR28","unstructured":"European Medicines Agency. Committee for Medicinal Products for Human Use (2006). Guideline on the choice of the non-inferiority margin (EMEA\/CPMP\/EWP\/2158\/99). https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-choice-non-inferiority-margin_en.pdf. Accessed 27 Apr 2023"},{"key":"6787_CR29","doi-asserted-by":"publisher","unstructured":"Alegre del Rey EJ et al (2014) Evaluaci\u00f3n y posicionamiento de medicamentos como alternativas terap\u00e9uticas equivalentes. Med Clin (Barc). https:\/\/doi.org\/10.1016\/j.medcli.2013.11.033","DOI":"10.1016\/j.medcli.2013.11.033"},{"key":"6787_CR30","unstructured":"Mar\u00edn R, Puigvent\u00f3s F, Fraga MD, Ortega A, L\u00f3pez-Briz E, Arocas V, Santos B (2013) Group for innovation, assessment, standardisation and research in the selection of drugs (GENESIS) of the spanish society of hospital pharmacy (SEFH). Support method for decision making in assessment and appraisal of medicines (MADRE). Version 4.0. Madrid: SEFH (ed.). https:\/\/gruposdetrabajo.sefh.es\/genesis\/genesis\/Documents\/MADRE%204_0_Procedures%20manual_Dec_2013.pdf. Accessed 23 May 2023"},{"key":"6787_CR31","unstructured":"European Medicines Agency (2017). Xeljanz\u00ae (tofacitinib) summary of product characteristics. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/xeljanz-epar-product-information_en.pdf. Accessed 27 Apr 2023"},{"key":"6787_CR32","unstructured":"European Medicines Agency (2017). Olumiant\u00ae (baricitinib) summary of product characteristics. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/olumiant-epar-product-information_en.pdf. Accessed 27 Apr 2023"},{"key":"6787_CR33","unstructured":"European Medicines Agency (2019). Rinvoq\u00ae (upadacitinib) summary of product characteristics. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/rinvoq-epar-product-information_en.pdf. Accessed 27 Apr 2023"},{"key":"6787_CR34","unstructured":"European Medicines Agency (2020). Jyseleca\u00ae (filgotinib) summary of product characteristics. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/jyseleca-epar-product-information_en.pdf. Accessed 27 Apr 2023"},{"key":"6787_CR35","unstructured":"European Medicines Agency (2023). EMA confirms measures to minimise risk of serious side effects with Janus kinase inhibitors for chronic inflammatory disorders. https:\/\/www.ema.europa.eu\/en\/documents\/referral\/janus-kinase-inhibitors-jaki-article-20-procedure-ema-confirms-measures-minimise-risk-serious-side_en.pdf. Accessed 27 Apr 2023"},{"key":"6787_CR36","unstructured":"Food and Drugs Administration (2021) Janus kinase (JAK) inhibitors: drug safety communication. FDA requires warnings about increased risk of serious heart-related events, cancer, blood clots and death. https:\/\/www.fda.gov\/safety\/medical-product-safety-information\/janus-kinase-jak-inhibitors-drug-safety-communication-fda-requires-warnings-about-increased-risk. Accessed 27 Apr 2023"},{"issue":"4","key":"6787_CR37","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1007\/s00393-020-00796-1","volume":"80","author":"YH Lee","year":"2021","unstructured":"Lee YH, Song GG (2021) Comparative efficacy and safety of tofacitinib, baricitinib, upadacitinib, and filgotinib in active rheumatoid arthritis refractory to biologic disease-modifying antirheumatic drugs. Z Rheumatol 80(4):379\u2013392. https:\/\/doi.org\/10.1007\/s00393-020-00796-1","journal-title":"Z Rheumatol"},{"issue":"4","key":"6787_CR38","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1111\/jcpt.13142","volume":"45","author":"YH Lee","year":"2020","unstructured":"Lee YH, Song GG (2020) Comparative efficacy and safety of tofacitinib, baricitinib, upadacitinib, filgotinib and peficitinib as monotherapy for active rheumatoid arthritis. J Clin Pharm Ther 45(4):674\u2013681. https:\/\/doi.org\/10.1111\/jcpt.13142","journal-title":"J Clin Pharm Ther"},{"issue":"8","key":"6787_CR39","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1007\/s00393-020-00750-1","volume":"79","author":"YH Lee","year":"2020","unstructured":"Lee YH, Song GG (2020) Relative efficacy and safety of tofacitinib, baricitinib, upadacitinib, and filgotinib in comparison to adalimumab in patients with active rheumatoid arthritis. Z Rheumatol 79(8):785\u2013796. https:\/\/doi.org\/10.1007\/s00393-020-00750-1","journal-title":"Z Rheumatol"},{"key":"6787_CR40","doi-asserted-by":"publisher","unstructured":"Lee YH, Song GG (2022) Relative remission rates of Janus kinase inhibitors in comparison with adalimumab in patients with active rheumatoid arthritis: a network meta-analysis. Z Rheumatol. https:\/\/doi.org\/10.1007\/s00393-022-01165-w","DOI":"10.1007\/s00393-022-01165-w"},{"key":"6787_CR41","volume-title":"Comparaci\u00f3n de la eficacia de filgotinib, tofacitinib, baricitinib y upadacitinib en artritis reumatoide","author":"R Claramunt Garc\u00eda","year":"2023","unstructured":"Claramunt Garc\u00eda R, Merino Almaz\u00e1n M, Sanchez Casanueva T (2023) Comparaci\u00f3n de la eficacia de filgotinib, tofacitinib, baricitinib y upadacitinib en artritis reumatoide. OFIL ILAPHAR"},{"key":"6787_CR42","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1056\/NEJMoa2008250","volume":"383","author":"A Rubbert-Roth","year":"2020","unstructured":"Rubbert-Roth A, Enejosa J, Pangan AL et al (2020) Trial of upadacitinib or abatacept in rheumatoid arthritis. N Engl J Med 383:1511\u20131521. https:\/\/doi.org\/10.1056\/NEJMoa2008250","journal-title":"N Engl J Med"},{"key":"6787_CR43","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1136\/ard-2022-223356","volume":"82","author":"JS Smolen","year":"2023","unstructured":"Smolen JS, Landew\u00e9 RBM, Bergstra SA et al (2023) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis 82:3. https:\/\/doi.org\/10.1136\/ard-2022-223356","journal-title":"Ann Rheum Dis"},{"key":"6787_CR44","unstructured":"European Medicines Agency (2018) Guideline on clinical investigation of medicinal products for the treatment of rheumatoid arthritis (CPMP\/EWP\/556\/95 Rev. 2). https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-clinical-investigation-medicinal-products-treatment-rheumatoid-arthritis_en.pdf. Accessed 27 Apr 2023"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-023-06787-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10067-023-06787-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-023-06787-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,11]],"date-time":"2023-11-11T18:04:31Z","timestamp":1699725871000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10067-023-06787-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,13]]},"references-count":44,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["6787"],"URL":"https:\/\/doi.org\/10.1007\/s10067-023-06787-2","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,13]]},"assertion":[{"value":"28 June 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 August 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 September 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 October 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This work has not been previously published and is not under consideration in the same or a substantially similar form (in print or electronically, including on a website), in any other peer-reviewed media. The present version of the manuscript has been seen and approved by all the authors who ensure the integrity of the work. This research has not received external funding. The manuscript does not contain clinical studies or patient data.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"L. V. V., I. G. G., A. M. F., G. G. A., A. R. M., A. P. D., C. M. M., and M. A. M. B. declare no conflict of interest. H. C. has received consultancy fees, research grants, and speaker\u2019s fees from Lilly, Galapagos, Abbvie, and Pfizer.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}